Logo Image
News
News
Academy
Multimedia
Editorial PodcastsEditorial VideosPeer ExchangeProfiles in MedicineShorts
Conferences
Conference CoverageConference Listing
More
Publications
Pharmaceutical Executive
Partner Perspectives
Resources
Content Engagement HubsE-BooksEventsSponsored PodcastsSponsored VideosWebcastsWhitepapers
Event Calendar

Subscribe

  • News
  • Academy
  • Multimedia
  • Conferences
  • Publications
  • Partner Perspectives
  • Resources
  • Event Calendar
  • Subscribe
  • Corporate Communications
    • Press Releases
    • Executive Roundtable
    • Executive Profiles
    • Leadership
  • Direct-to-Consumer
    • Patient Education
    • Healthcare Access
    • Telehealth
  • Emerging Biopharma
    • Partnerships
    • Funding
  • IR Licensing and Partnerships
    • Finance
    • Industry Trends
  • Market Access
    • Patient Access
    • Pricing
    • Strategy
  • Medical Affairs
    • Patient Advocacy
    • Clinical Data
    • Pharmacovigilance
  • Operations
    • Sustainability
    • Technology
    • R&D/Clinical Trials
    • Supply Chain
  • Patient Engagement
    • DE&I
  • Regulatory
    • FDA
    • Legal
    • Global
  • Sales & Marketing
    • Sales Effectiveness
    • Campaigns
    • DTC Marketing
    • Medical Education
Spotlight -
Emerging Pharma Leaders Awards|
Latest Executive Roundtables|
Asembia 2026|
Sales Effectiveness
Advertisement

Robert L. Stoll

Advertisement

Articles by Robert L. Stoll

Attacks on Pharmaceutical Improvement Patents

ByRobert L. Stoll,Nick Colic
August 21st 2019

Pharmaceutical Executive

Is Congress harming pharmaceutical research by limiting enforcement of improvement patents?

Advertisement

Latest Updated Articles

  • Attacks on Pharmaceutical Improvement Patents
    Attacks on Pharmaceutical Improvement Patents

    August 21st 2019



Advertisement
Advertisement

Trending on PharmExec

1

Modern Policy Concerns Stemming from 340B

2

Funding Roundup: Silence Therapeutics, AbCellera Announce IPO Pricing, Beyang, Remepy Close Series A Financing

3

Pharmaceutical Executive Daily: Mereo BioPharma Enters Option and License Agreement with Sentynl Therapeutics

4

2026 Emerging Pharma Leaders

5

Taking a Hard Look at Pharma's Traditional Margin Model

  • About
  • Advertise
  • Contact Us
  • Editorial Board
  • Editorial Submission Guidelines
  • Do Not Sell My Personal Information
  • Privacy Policy
  • Terms and Conditions
Contact Info

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

Brand Logo

© 2026 MJH Life Sciences®

All rights reserved.

Home
About Us
News
Contact Us